No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis

被引:8
作者
Padberg, F
Haase, CG
Feneberg, W
Schwarz, MJ
Hampel, H
机构
[1] Univ Munich, Dept Psychiat, D-80336 Munich, Germany
[2] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[3] Marianne Strauss Hosp, Multiple Sclerosis Ctr, D-82335 Kempfenhausen, Germany
关键词
interleukin-8; soluble interleukin-6 receptor; soluble glycoprotein 130; myelin-oligodendrocyte glycoprotein; cerebrospinal fluid; serum;
D O I
10.1016/S0304-3940(01)01792-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Myelin-oligodendrocyte glycoprotein (MOG) specific antibodies tabs) are involved in autoantibody-mediated demyelination possibly contributing to lesion development in multiple sclerosis (MS). Interleukin-6 (IL-6) has been reported to play a crucial role for the pathogenesis of a MOG-induced animal model of MS. To investigate the link between anti-MOG abs production and IL-6 up-regulation in MS we determined the presence of anti-MOG abs and measured concentrations of IL-6 and its soluble receptors (sIL-6RC) in paired serum and cerebrospinal fluid (CSF) samples of MS patients and serum samples of age-matched healthy controls (HC). Anti-MOG abs were detected in 75% of MS sera, 57% of MS CSF samples and 20% of HC sera. There was no difference in IL-6 and sIL-6RC levels between anti-MOG abs positive and negative samples. Thus, no association between the presence of anti-MOG abs and serum/CSF levels of IL-6/sIL-6RC was found. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:13 / 16
页数:4
相关论文
共 24 条
  • [1] Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO
  • [2] 2-D
  • [3] FREI K, 1991, J NEUROIMMUNOL, V31, P147
  • [4] Identification of autoantibodies associated with myelin damage in multiple sclerosis
    Genain, CP
    Cannella, B
    Hauser, SL
    Raine, CS
    [J]. NATURE MEDICINE, 1999, 5 (02) : 170 - 175
  • [5] Biotechnological agents for the immunotherapy of multiple sclerosis - Principles, problems and perspectives
    Hohlfeld, R
    [J]. BRAIN, 1997, 120 : 865 - 916
  • [6] KARMI A, 1999, ARCH NEUROL-CHICAGO, V56, P311
  • [7] Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
    Lindert, RB
    Haase, CG
    Brehm, U
    Linington, C
    Wekerle, H
    Hohlfeld, R
    [J]. BRAIN, 1999, 122 : 2089 - 2099
  • [8] Defining the clinical course of multiple sclerosis: Results of an international survey
    Lublin, FD
    Reingold, SC
    [J]. NEUROLOGY, 1996, 46 (04) : 907 - 911
  • [9] Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO
  • [10] 2-#